Benjamin Enerson

Consigliere Generale presso THESEUS PHARMACEUTICALS, INC.

Health Technology

Consumer Services

Health Services

Profilo

Benjamin Enerson is currently working as Vice President-Legal Affairs at Theseus Pharmaceuticals, Inc. Prior to this, he worked as General Counsel at Finch Therapeutics Group, Inc. and Tremeau Pharmaceuticals, Inc. He completed his undergraduate degree from Vanderbilt University and his graduate degree from Cornell Law School in 2004.

Posizioni attive di Benjamin Enerson

Società	Posizione	Inizio
THESEUS PHARMACEUTICALS, INC.	Consigliere Generale	-

Tutte le posizioni attive di Benjamin Enerson

Precedenti posizioni note di Benjamin Enerson

Società	Posizione	Fine
FINCH THERAPEUTICS GROUP, INC.	Consigliere Generale	-
Tremeau Pharmaceuticals, Inc. Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA.	Consigliere Generale	-

Vedi nel dettaglio l'esperienza di Benjamin Enerson

Formazione di Benjamin Enerson

Cornell Law School	Graduate Degree
Vanderbilt University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Benjamin Enerson

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
FINCH THERAPEUTICS GROUP, INC.	Health Services

Aziende private	2
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.	Health Technology
Tremeau Pharmaceuticals, Inc. Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA.	Health Technology